TN2009000028A1 - Agonistes de ep2 - Google Patents

Agonistes de ep2

Info

Publication number
TN2009000028A1
TN2009000028A1 TN2009000028A TN2009000028A TN2009000028A1 TN 2009000028 A1 TN2009000028 A1 TN 2009000028A1 TN 2009000028 A TN2009000028 A TN 2009000028A TN 2009000028 A TN2009000028 A TN 2009000028A TN 2009000028 A1 TN2009000028 A1 TN 2009000028A1
Authority
TN
Tunisia
Prior art keywords
agonists
compounds
processes
preparation
methods
Prior art date
Application number
TN2009000028A
Other languages
English (en)
Inventor
Ganesh Prasanna
Charles Floyd Bosworth
Fontaine Jennifer Anne La
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TN2009000028A1 publication Critical patent/TN2009000028A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention propose des agonistes de EP2 des procédés pour leur préparation, des compositions pharmaceutiques contenant ces composés, et des méthodes d'utilisation de ces composés et compositions pour abaisser la pression intraoculaire et traiter ainsi Ie glaucome.
TN2009000028A 2006-07-28 2009-01-26 Agonistes de ep2 TN2009000028A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83390706P 2006-07-28 2006-07-28
US94192307P 2007-06-04 2007-06-04
PCT/IB2007/002044 WO2008015517A2 (fr) 2006-07-28 2007-07-16 Agonistes de ep2

Publications (1)

Publication Number Publication Date
TN2009000028A1 true TN2009000028A1 (fr) 2010-08-19

Family

ID=38896126

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2009000028A TN2009000028A1 (fr) 2006-07-28 2009-01-26 Agonistes de ep2

Country Status (26)

Country Link
US (2) US7622475B2 (fr)
EP (1) EP2059507B1 (fr)
JP (1) JP4583500B2 (fr)
KR (1) KR101088942B1 (fr)
AP (1) AP2009004754A0 (fr)
AR (1) AR062122A1 (fr)
AU (1) AU2007280130B2 (fr)
BR (1) BRPI0714683A2 (fr)
CA (1) CA2659184C (fr)
CL (1) CL2007002207A1 (fr)
CR (1) CR10554A (fr)
EA (1) EA200970067A1 (fr)
EC (1) ECSP099071A (fr)
GT (1) GT200700064A (fr)
HK (1) HK1133876A1 (fr)
IL (1) IL196355A0 (fr)
MA (1) MA30604B1 (fr)
MX (1) MX2009001062A (fr)
NO (1) NO20090738L (fr)
NZ (1) NZ573964A (fr)
PE (1) PE20080408A1 (fr)
RS (1) RS20090002A (fr)
TN (1) TN2009000028A1 (fr)
TW (1) TWI372757B (fr)
UY (1) UY30511A1 (fr)
WO (1) WO2008015517A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8648097B2 (en) * 2008-03-12 2014-02-11 Ube Industries, Ltd. Pyridylaminoacetic acid compound
PL2415763T3 (pl) 2009-03-30 2016-05-31 Ube Industries Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry
WO2011030873A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés benzyliques
WO2011030865A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés benzyliques substitués
WO2011030871A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés hétéroaryle n-substitués
AU2010293410A1 (en) * 2009-09-11 2012-05-03 Ube Industries, Ltd. Substituted carbonyl compounds
KR20120068902A (ko) * 2009-09-11 2012-06-27 우베 고산 가부시키가이샤 아닐린 화합물
WO2011030872A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés sulfonamide
CN102666490A (zh) * 2009-12-25 2012-09-12 宇部兴产株式会社 氨基吡啶化合物
RU2013111281A (ru) * 2010-08-17 2014-09-27 Аллерган, Инк. Агонисты ер2 или ер4 для лечения помутнения роговицы
EA026702B1 (ru) 2011-09-16 2017-05-31 Санофи Производные анилина, их получение и терапевтическое применение
WO2013109991A1 (fr) * 2012-01-20 2013-07-25 Acucela Inc. Composés hétérocycliques substitués pour le traitement d'une maladie
CA2867527A1 (fr) 2012-05-03 2013-11-07 Takeda Gmbh Nouveaux agonistes du recepteur ep2
US9339496B2 (en) 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
TW201527282A (zh) * 2013-03-28 2015-07-16 Ube Industries 取代聯芳基化合物
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び／又は予防のための医薬組成物
JP2017206443A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換ビアリール化合物及び他の医薬の組み合わせ
RU2749952C2 (ru) * 2015-07-01 2021-06-21 Сантэн Фармасьютикал Ко., Лтд. Депо-препарат, содержащий сложный эфир лимонной кислоты

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP1000619A3 (fr) 1998-06-23 2002-07-24 Pfizer Products Inc. Méthode de traitement du glaucome
IL139941A0 (en) 1999-12-02 2002-02-10 Pfizer Prod Inc Use of prostaglandin agonists to treat erectile dysfunction or impotence
US20020161026A1 (en) 2000-11-07 2002-10-31 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
NZ532209A (en) 2001-11-30 2007-05-31 Pfizer Prod Inc Controlled release microparticle pharmaceutical composition for the sustained release of an EP2 receptor selective agonist for treating bone injury or bone defect
CA2473984A1 (fr) * 2002-01-31 2003-08-07 Pfizer Products Inc. Metabolites d'acide (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetique
AU2004216898A1 (en) 2003-03-04 2004-09-16 Pfizer Products Inc. Use of EP2 selective receptor agonists in medical treatment
US20050203086A1 (en) 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma

Also Published As

Publication number Publication date
EA200970067A1 (ru) 2009-08-28
AP2009004754A0 (en) 2009-02-28
UY30511A1 (es) 2008-02-29
HK1133876A1 (en) 2010-04-09
KR20090023507A (ko) 2009-03-04
MX2009001062A (es) 2009-02-06
EP2059507B1 (fr) 2013-03-20
US7622475B2 (en) 2009-11-24
AU2007280130A1 (en) 2008-02-07
WO2008015517A3 (fr) 2008-06-12
WO2008015517A2 (fr) 2008-02-07
CL2007002207A1 (es) 2008-02-01
US20100105905A1 (en) 2010-04-29
CR10554A (es) 2009-02-10
CA2659184A1 (fr) 2008-02-07
NZ573964A (en) 2010-11-26
EP2059507A2 (fr) 2009-05-20
PE20080408A1 (es) 2008-04-28
AU2007280130B2 (en) 2011-09-22
TW200817360A (en) 2008-04-16
MA30604B1 (fr) 2009-07-01
CA2659184C (fr) 2012-02-21
RS20090002A (en) 2010-06-30
US20080045545A1 (en) 2008-02-21
IL196355A0 (en) 2009-09-22
GT200700064A (es) 2009-06-18
KR101088942B1 (ko) 2011-12-01
TWI372757B (en) 2012-09-21
BRPI0714683A2 (pt) 2013-03-26
AR062122A1 (es) 2008-10-15
JP2009544751A (ja) 2009-12-17
JP4583500B2 (ja) 2010-11-17
NO20090738L (no) 2009-04-27
ECSP099071A (es) 2009-02-27

Similar Documents

Publication Publication Date Title
TN2009000028A1 (fr) Agonistes de ep2
MA35576B1 (fr) Nouveaux composés
TN2011000454A1 (fr) Derives de benzofurannyle utilises comme inhibiteurs de glucokinase
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
TNSN08139A1 (fr) Composes therapeutiques
MA31419B1 (fr) Derives de pyridine
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA31953B1 (fr) Nouveaux derives du thiophene.
MA31683B1 (fr) Composes et procedes pour moduler fxr
TNSN08137A1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA34599B1 (fr) Compositions pharmaceutiques contenant un inhibiteur dgat1
MA30629B1 (fr) Derives de pyrazole servant d'inhibiteurs du cytochrome p450
MA35638B1 (fr) 2-thiopyrimidinones
MA49127B1 (fr) Dérivés d'indole n-substitués
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
MA32506B1 (fr) Nouveaux composes